Within the field of oncology, the integration of targeted treatments based on biomarkers and genomic testing into the standard of care for multiple cancer types has resulted in improved patient outcomes. However, while this technology has been effectively implemented within comprehensive cancer centers and large academic institutions, community-based oncology settings are often unable to do so effectively. It is imperative that clinicians practicing in a community oncology setting are up to date on the latest information regarding genetic/biomarker testing and targeted treatments, in order to improve equity in outcomes for patients with cancer from all backgrounds.
In the first installment of this CME Outfitters Snack series, expert faculty will guide learners through an overview of challenges and recent developments in immunotherapy, as well as guideline recommendations on their implementation in practice. Faculty will also detail strategies designed to increase implementation of best practices in genetic and biomarker testing for cancer immunotherapy.
Implement best practices in genetic and biomarker testing for cancer immunotherapy.
Supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists specializing in pathology, oncology or surgical oncology caring for patients with cancer in community settings
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Arun reports the following financial relationships:
Grants: Department of Defense (DOD); Cancer Prevention & Research Institute of Texas (CPRIT); National Cancer Institute (NCI); and Susan G. Komen
Research Support: AstraZeneca (paid to the institution)
Dr. Schalper reports the following financial relationships:
Advisory Board: AstraZeneca; Bristol Myers Squibb; EMD Serono; Genmab; Merck & Co., Inc.; Molecular Templates, Inc.; OnCusp; Parthenon Therapeutics Inc.; Shattuck Labs, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Torque Therapeutics/Repertoire Immune Medicines
Consultant: Agenus Inc.; Clinica Alemana Santiago; Roche; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Akoya Biosciences; AstraZeneca; Boehringer-Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Merck & Co., Inc.; Moderna, Inc.; Navigate BioPharma Services, Inc.; Pierre Fabre; Ribon Therapeutics; Roche; Surface Oncology; Takeda Pharmaceuticals U.S.A., Inc.; and Tesaro/GSK
Speakers Bureau: Forefront Collaborative and PeerView
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).